{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:38:33Z","timestamp":1792640313168,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"DOI":"10.1007\/s00408-026-00952-5","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:53:09Z","timestamp":1792637589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase 3 Antifibrotic-Directed Therapy Outcomes in Idiopathic Pulmonary Fibrosis: Beyond FVC Decline"],"prefix":"10.1007","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0214-1571","authenticated-orcid":false,"given":"Fumihiro","family":"Kashizaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3013-405X","authenticated-orcid":false,"given":"Shohei","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0393-4388","authenticated-orcid":false,"given":"Ryusuke","family":"Orii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8951-3203","authenticated-orcid":false,"given":"Hanming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2099-5512","authenticated-orcid":false,"given":"Junki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0853-211X","authenticated-orcid":false,"given":"Takumi","family":"Takagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7998-5684","authenticated-orcid":false,"given":"Reeko","family":"Osada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9716-4627","authenticated-orcid":false,"given":"Mai","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1344-5052","authenticated-orcid":false,"given":"Kentaro","family":"Yumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6406-6138","authenticated-orcid":false,"given":"Harumi","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"9","key":"952_CR1","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 205(9):e18\u2013e47. https:\/\/doi.org\/10.1164\/rccm.202202-0399ST","journal-title":"Am J Respir Crit Care Med"},{"issue":"10082","key":"952_CR2","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/s0140-6736(17)30866-8","volume":"389","author":"L Richeldi","year":"2017","unstructured":"Richeldi L, Collard HR, Jones MG (2017) Idiopathic pulmonary fibrosis. Lancet 389(10082):1941\u20131952. https:\/\/doi.org\/10.1016\/s0140-6736(17)30866-8","journal-title":"Lancet"},{"issue":"2","key":"952_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/s2213-2600(22)00475-1","volume":"11","author":"M Selman","year":"2023","unstructured":"Selman M, Pardo A, Wells AU (2023) Usual interstitial pneumonia as a stand-alone diagnostic entity: the case for a paradigm shift? Lancet Respir Med 11(2):188\u2013196. https:\/\/doi.org\/10.1016\/s2213-2600(22)00475-1","journal-title":"Lancet Respir Med"},{"issue":"12","key":"952_CR4","doi-asserted-by":"publisher","first-page":"e70521","DOI":"10.1002\/mco2.70521","volume":"6","author":"L Zuo","year":"2025","unstructured":"Zuo L, Liu Q, Ye D, Fan J, Wu L (2025) Idiopathic pulmonary fibrosis: cellular heterogeneity, mechanisms, and therapeutic implications. MedComm (2020) 6(12):e70521. https:\/\/doi.org\/10.1002\/mco2.70521","journal-title":"MedComm (2020)"},{"issue":"2","key":"952_CR5","doi-asserted-by":"publisher","first-page":"C483","DOI":"10.1152\/ajpcell.00239.2023","volume":"325","author":"T Parimon","year":"2023","unstructured":"Parimon T, Chen P, Stripp BR, Liang J, Jiang D, Noble PW et al (2023) Senescence of alveolar epithelial progenitor cells: a critical driver of lung fibrosis. Am J Physiol Cell Physiol 325(2):C483\u2013C495. https:\/\/doi.org\/10.1152\/ajpcell.00239.2023","journal-title":"Am J Physiol Cell Physiol"},{"key":"952_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01484-2024","author":"HY Yoon","year":"2025","unstructured":"Yoon HY, Kim H, Bae Y, Song JW (2025) Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01484-2024","journal-title":"Eur Respir J"},{"key":"952_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212179","author":"AV Samarelli","year":"2021","unstructured":"Samarelli AV, Masciale V, Aramini B, Col\u00f3 GP, Tonelli R, Marchioni A et al (2021) Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222212179","journal-title":"Int J Mol Sci"},{"issue":"8","key":"952_CR8","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1002\/rcr2.70010","volume":"12","author":"F Kashizaki","year":"2024","unstructured":"Kashizaki F, Matsumoto S, Miyasaka A, Tsuchiya N, Osada R, Kaneko M et al (2024) Effectiveness of upfront triple oral combination therapy with additional pirfenidone in a patient with severe pulmonary hypertension associated with lung diseases. Respirol Case Rep 12(8):e70010. https:\/\/doi.org\/10.1002\/rcr2.70010","journal-title":"Respirol Case Rep"},{"issue":"10","key":"952_CR9","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","volume":"156","author":"B Ley","year":"2012","unstructured":"Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS et al (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156(10):684\u2013691. https:\/\/doi.org\/10.7326\/0003-4819-156-10-201205150-00004","journal-title":"Ann Intern Med"},{"issue":"4","key":"952_CR10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1183\/09031936.00005209","volume":"35","author":"H Taniguchi","year":"2010","unstructured":"Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M et al (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35(4):821\u2013829. https:\/\/doi.org\/10.1183\/09031936.00005209","journal-title":"Eur Respir J"},{"issue":"9779","key":"952_CR11","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/s0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377(9779):1760\u20131769. https:\/\/doi.org\/10.1016\/s0140-6736(11)60405-4","journal-title":"Lancet"},{"issue":"22","key":"952_CR12","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King","year":"2014","unstructured":"King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370(22):2083\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1402582","journal-title":"N Engl J Med"},{"issue":"22","key":"952_CR13","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071\u20132082. https:\/\/doi.org\/10.1056\/NEJMoa1402584","journal-title":"N Engl J Med"},{"issue":"1","key":"952_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1183\/13993003.00026-2015","volume":"47","author":"PW Noble","year":"2016","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA et al (2016) Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 47(1):243\u2013253. https:\/\/doi.org\/10.1183\/13993003.00026-2015","journal-title":"Eur Respir J"},{"issue":"1","key":"952_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s2213-2600(16)30326-5","volume":"5","author":"SD Nathan","year":"2017","unstructured":"Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK et al (2017) Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med 5(1):33\u201341. https:\/\/doi.org\/10.1016\/s2213-2600(16)30326-5","journal-title":"Lancet Respir Med"},{"issue":"22","key":"952_CR16","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","volume":"392","author":"L Richeldi","year":"2025","unstructured":"Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ et al (2025) Nerandomilast in patients with idiopathic pulmonary fibrosis. N Engl J Med 392(22):2193\u20132202. https:\/\/doi.org\/10.1056\/NEJMoa2414108","journal-title":"N Engl J Med"},{"key":"952_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ajrccm\/aamag058","author":"JM Oldham","year":"2026","unstructured":"Oldham JM, Azuma A, Kreuter M, Maher TM, Martinez FJ, Richeldi L et al (2026) Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial. Am J Respir Crit Care Med. 212(5):972\u2013980. https:\/\/doi.org\/10.1093\/ajrccm\/aamag058","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"952_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jama.2024.8693","volume":"332","author":"G Raghu","year":"2024","unstructured":"Raghu G, Richeldi L, Fern\u00e1ndez P\u00e9rez ER, De Salvo MC, Silva RS, Song JW et al (2024) Pamrevlumab for idiopathic pulmonary fibrosis: the ZEPHYRUS-1 randomized clinical trial. JAMA 332(5):380\u2013389. https:\/\/doi.org\/10.1001\/jama.2024.8693","journal-title":"JAMA"},{"issue":"2","key":"952_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa2501488","volume":"395","author":"SD Nathan","year":"2026","unstructured":"Nathan SD, Smith P, Deng C, King CS, De Salvo M, Weigt SS et al (2026) Phase 3 trials of inhaled treprostinil for idiopathic pulmonary fibrosis. N Engl J Med 395(2):115\u2013126. https:\/\/doi.org\/10.1056\/NEJMoa2501488","journal-title":"N Engl J Med"},{"key":"952_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512911","author":"SD Nathan","year":"2026","unstructured":"Nathan SD, Smith P, Deng C, De Salvo M, Wuyts W, Pavie-Gallegos J et al (2026) Inhaled treprostinil for idiopathic pulmonary fibrosis. N Engl J Med. 395(2):127\u2013137. https:\/\/doi.org\/10.1056\/NEJMoa2512911","journal-title":"N Engl J Med"},{"issue":"4","key":"952_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","volume":"62","author":"SM Ruwanpura","year":"2020","unstructured":"Ruwanpura SM, Thomas BJ, Bardin PG (2020) Pirfenidone: molecular mechanisms and potential clinical applications in lung disease. Am J Respir Cell Mol Biol 62(4):413\u2013422. https:\/\/doi.org\/10.1165\/rcmb.2019-0328TR","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"952_CR22","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S et al (2015) Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 45(5):1434\u20131445. https:\/\/doi.org\/10.1183\/09031936.00174914","journal-title":"Eur Respir J"},{"key":"952_CR23","doi-asserted-by":"publisher","first-page":"838449","DOI":"10.3389\/fphar.2022.838449","volume":"13","author":"FE Herrmann","year":"2022","unstructured":"Herrmann FE, Hesslinger C, Wollin L, Nickolaus P (2022) BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front Pharmacol 13:838449. https:\/\/doi.org\/10.3389\/fphar.2022.838449","journal-title":"Front Pharmacol"},{"issue":"4","key":"952_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.13-1474","volume":"145","author":"CJ Ryerson","year":"2014","unstructured":"Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD et al (2014) Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 145(4):723\u2013728. https:\/\/doi.org\/10.1378\/chest.13-1474","journal-title":"Chest"},{"issue":"4","key":"952_CR25","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/thoraxjnl-2021-218440","volume":"78","author":"A Chandel","year":"2023","unstructured":"Chandel A, Pastre J, Valery S, King CS, Nathan SD (2023) Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis. Thorax 78(4):368\u2013375. https:\/\/doi.org\/10.1136\/thoraxjnl-2021-218440","journal-title":"Thorax"},{"key":"952_CR26","unstructured":"Kashizaki F, Watanabe S, Orii R, Yumoto K. Comparative efficacy of antifibrotic therapies in idiopathic pulmonary fibrosis: a systematic review and network meta-analysis of phase III randomized placebo-controlled trials https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261332510."},{"key":"952_CR27","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2020) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"952_CR28","doi-asserted-by":"publisher","first-page":"14898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:14898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"952_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12890-015-0034-y","volume":"15","author":"E Loveman","year":"2015","unstructured":"Loveman E, Copley VR, Scott DA, Colquitt JL, Clegg AJ, O\u2019Reilly KM (2015) Comparing new treatments for idiopathic pulmonary fibrosis\u2013a network meta-analysis. BMC Pulm Med 15:37. https:\/\/doi.org\/10.1186\/s12890-015-0034-y","journal-title":"BMC Pulm Med"},{"issue":"5","key":"952_CR30","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.69854\/jcq.2025.0022","volume":"2","author":"Y Tagami","year":"2025","unstructured":"Tagami Y, Kawai M, Okamura K, Kitamura H (2025) Oral antifibrotic agents for the treatment of progressive pulmonary fibrosis: a systematic review and network meta-analysis of randomized controlled trials. J Clin Quest 2(5):e86. https:\/\/doi.org\/10.69854\/jcq.2025.0022","journal-title":"J Clin Quest"},{"issue":"2","key":"952_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1148\/radiol.2392041968","volume":"239","author":"WR Webb","year":"2006","unstructured":"Webb WR (2006) Thin-section CT of the secondary pulmonary lobule: anatomy and the image--the 2004 Fleischner lecture. Radiology 239(2):322\u2013338. https:\/\/doi.org\/10.1148\/radiol.2392041968","journal-title":"Radiology"},{"issue":"1","key":"952_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.resinv.2016.08.005","volume":"55","author":"M Ebina","year":"2017","unstructured":"Ebina M (2017) Pathognomonic remodeling of blood and lymphatic capillaries in idiopathic pulmonary fibrosis. Respir Investig 55(1):2\u20139. https:\/\/doi.org\/10.1016\/j.resinv.2016.08.005","journal-title":"Respir Investig"},{"issue":"1","key":"952_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12890-025-03916-2","volume":"25","author":"F Lalla","year":"2025","unstructured":"Lalla F, Latella A, Varone F, Iovene B, Richeldi L, Sgalla G (2025) Long-term treatment with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a comparative, real-world cohort study. BMC Pulm Med 25(1):455. https:\/\/doi.org\/10.1186\/s12890-025-03916-2","journal-title":"BMC Pulm Med"},{"key":"952_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21037\/tgh-25-104","volume":"11","author":"X Ou","year":"2026","unstructured":"Ou X, Wu Y, Cheng Q, Yin W, Rong C, He S et al (2026) Clinical profiles and risk predictors of drug-induced liver injury from pirfenidone and nintedanib used to treat idiopathic pulmonary fibrosis: a real-world analysis of a tertiary Chinese hospital cohort combined with FAERS data mining. Transl Gastroenterol Hepatol 11:9. https:\/\/doi.org\/10.21037\/tgh-25-104","journal-title":"Transl Gastroenterol Hepatol"},{"key":"952_CR35","doi-asserted-by":"publisher","first-page":"1586197","DOI":"10.3389\/fphar.2025.1586197","volume":"16","author":"S Majewski","year":"2025","unstructured":"Majewski S, G\u00f3rska K, Lewandowska KB, Martusewicz-Boros MM, Sobiecka M, Piotrowski WJ (2025) Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland. Front Pharmacol 16:1586197. https:\/\/doi.org\/10.3389\/fphar.2025.1586197","journal-title":"Front Pharmacol"},{"issue":"5","key":"952_CR36","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.chest.2023.11.035","volume":"165","author":"JS Kim","year":"2024","unstructured":"Kim JS, Murray S, Yow E, Anstrom KJ, Kim HJ, Flaherty KR et al (2024) Comparison of Pirfenidone and Nintedanib: post Hoc Analysis of the CleanUP-IPF Study. Chest 165(5):1163\u20131173. https:\/\/doi.org\/10.1016\/j.chest.2023.11.035","journal-title":"Chest"},{"key":"952_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cells11010143","author":"K Takehara","year":"2022","unstructured":"Takehara K, Koga Y, Hachisu Y, Utsugi M, Sawada Y, Saito Y et al (2022) Differential discontinuation profiles between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. Cells. https:\/\/doi.org\/10.3390\/cells11010143","journal-title":"Cells"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00952-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-026-00952-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00952-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:53:12Z","timestamp":1792637592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-026-00952-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1007\/s00408-026-00952-5","relation":{},"ISSN":["1432-1750"],"issn-type":[{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"30 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest related to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required because this study is a systematic review and descriptive analysis of previously published aggregate data and did not involve prospective recruitment, intervention, or access to individual patient records. No unpublished patient data or identifiable clinical images were included in this manuscript.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"87"}}